{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreighqvwnhzist3vbw6tfrodxs2aq7tvu2jrrwkhir632br6o47iy34",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mk2idixhxul2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiasyb5rcir7hajc35w5d4qc6r27kpjzlwdpfue3zxsl7v4gsalxbq"
    },
    "mimeType": "image/jpeg",
    "size": 51379
  },
  "path": "/2026/04/21/aacr-2026-pancreatic-cancer-revolution-medicines-future/?utm_campaign=rss",
  "publishedAt": "2026-04-21T23:03:12.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "In the Lab",
    "Pharma",
    "AACR",
    "biotechnology",
    "Cancer",
    "drug development",
    "research",
    "STAT+"
  ],
  "textContent": "A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a generation beyond.",
  "title": "STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it",
  "updatedAt": "2026-04-21T23:47:38.000Z"
}